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OBJECTIVES In patients with coronary artery disease (CAD), we sought to demonstrate normal myocardial
blood flow (MBF) and myocardial oxygen consumption (MMRO2) to post-ischemic
myocardium that exhibited reversible dysfunction and the relation between the severity of the
dysfunction and the preceding ischemia.
BACKGROUND In animal models of stunning, MBF and MMRO2 are normal or near normal, and the
severity of stunning is related to the degree of the preceding ischemia.
METHODS Myocardial blood flow and MMRO2 were measured using positron emission tomography and
oxygen 15-labelled water (H2
15O) and oxygen 15-labelled oxygen (15O2), respectively, in 14
patients with CAD and normal left ventricular (LV) function. Global ejection fraction and
regional LV systolic function (SF) were measured using quantitative echocardiography during
and after dobutamine-induced ischemia.
RESULTS Ejection fraction and SF were reduced 30 min after dobutamine (both: p  0.01) but
recovered by 120 min. Myocardial blood flow (ml/min per g) to regions with reversible LV
dysfunction was normal at baseline and during dysfunction (0.88 [0.82 to 0.99] and 1.09 [0.75
to 1.37], respectively, p  NS) as was MMRO2 (ml/min per 100 g) (16.64 [10.16 to 16.18]
and 11.68 [8.43 to 15.30] respectively, p  NS). Left ventricular dysfunction was related to
stenosis severity and peak MBF. Regions were divided into those subtended by a stenosis of
50%, 50% to 80% and 80% luminal diameter. Systolic function 30 min after dobutamine
was 93.9% (83.4% to 104.4%) (p  NS), 85.4% (80.0% to 90.9%) and 67.4% (56.2% to
78.7%) (both: p  0.001), respectively. Peak MBF was 2.0 (1.71 to 2.31), 1.75 (1.65 to 1.85)
(p  0.01 compared with 50%) and 1.47 (1.33 to 1.60) (p  0.03 compared with 50% to
80% and p  0.002 compared with 50%), respectively.
CONCLUSIONS In patients with CAD, dobutamine produces prolonged, but reversible, LV dysfunction when
MBF is normal, confirming stunning. This stunning is related to the severity of the coronary
stenosis and the reduction in peak MBF. Myocardial oxygen consumption to stunned
myocardium is normal. (J Am Coll Cardiol 2002;39:420–7) © 2002 by the American
College of Cardiology
Post-ischemic left ventricular (LV) dysfunction without
irreversible myocyte damage and in the presence of normal
or near-normal myocardial blood flow (MBF) is the hall-
mark of myocardial stunning (1,2). This phenomenon has
been well described and characterized in a number of animal
models after ischemia (induced by coronary occlusion) and
reperfusion (3,4) and after exercise-induced (i.e., demand)
ischemia (5,6). In such animal experiments, the severity of
myocardial stunning is related to both the degree and
duration of the preceding ischemic episode (7). In patients
with coronary artery disease (CAD), demand ischemia may
lead to reversible LV dysfunction that is perceived as
stunning on the basis of normal MBF that has been inferred
from studies using single photon emission computed to-
mography (SPECT) (8). However, SPECT provides, at
best, semiquantitative data, while positron emission tomog-
raphy (PET) enables MBF to be measured quantitatively.
To establish whether such reversible post-ischemic LV
dysfunction is indeed stunning, this study used PET to
measure absolute MBF and myocardial oxygen consump-
tion (MMRO2) in patients with CAD and normal resting
LV function.
METHODS
Patient selection. We enrolled 18 male patients (mean age
63  8 years) with chronic stable angina pectoris. All had
normal resting LV function and CAD with a 70%
stenosis in at least one major epicardial coronary artery
assessed using quantitative coronary angiography (QCA-
CMS, Medis, Leiden, the Netherlands) within the preced-
ing four months. Patients were excluded if there was a
history of myocardial infarction or unstable angina in the
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preceding four months or if it was not possible to obtain
echocardiograms of sufficient quality for quantitative anal-
ysis. All patients were taking aspirin in addition to their
anti-anginal medication (Table 1).
Study protocol. Beta-adrenergic blocking agents and cal-
cium antagonists were withdrawn 72 h before the study, and
other anti-anginal medication omitted on the day of the
study. Patients were asked to avoid activities that might
precipitate angina for 12 h before the study and were
excluded if they had suffered angina or used glyceryl
trinitrate within 4 h before the study. Left ventricular
function was assessed by transthoracic echocardiography
before symptom-limited dobutamine stress and during re-
covery. Myocardial blood flow was measured with PET and
oxygen 15-labelled water (H2
15O) at baseline, at peak stress
and at 12.5 min after termination of dobutamine stress. The
myocardial metabolic rate of MMRO2 was measured by
inhalation of oxygen 15-labelled oxygen (15O2) before the
administration of dobutamine and again after the final
H2
15O scan. The study was approved by the Research
Ethics Committee of Hammersmith Hospital, and radia-
tion exposure was licensed by the United Kingdom Admin-
istration of Radioactive Substances Advisory Committee
(ARSAC). All patients gave fully informed written consent.
Echocardiography. Two-dimensional echocardiography
was performed by one operator (E.B.) with the patient in
the left lateral position using commercially available equip-
ment with a P3-2 Broadband phased array transducer (HDI
3000, ATL Ltd., Bothell, Washington). Images were re-
corded at baseline and then 30, 45, 60 and 120 min after
peak dobutamine. To minimize beat-to-beat variability, all
recordings were made in held midexpiration (9) and re-
corded onto super VHS videotape for off-line analysis. Left
ventricular contractile function was assessed in the apical
two-chamber (AP2CH) and apical four-chamber (AP4CH)
views according to the guidelines from the American
Society of Echocardiography (10).
Dobutamine stress. Dobutamine was infused at incremen-
tal doses (starting at 5 g/kg per min and increased at
3-min intervals to 10, 15, 20, 30 and 40 g/kg per min)
until patients experienced chest pain, were limited by other
symptoms, achieved a target heart rate (calculated as 220 
age in years), systolic blood pressure fell by 20 mm Hg or
significant arrhythmias were induced. The electrocardio-
gram (ECG) was monitored continuously, and blood pres-
sure and a 12-lead ECG recorded every 3 min during stress
and every 5 min during recovery.
Echocardiographic analysis. The videotaped images were
analyzed using a PC-based digitizing program (Thorax-
center, Erasmus University, Rotterdam, the Netherlands)
(9). Three consecutive beats (excluding extrasystolic and
post-extrasystolic beats) were analyzed for each time point.
Endocardial borders (excluding papillary muscles) were
Abbreviations and Acronyms
AP2CH  apical two-chamber
AP4CH  apical four-chamber
CAD  coronary artery disease
C15O  oxygen 15-labelled carbon monoxide
EF  ejection fraction
H2
15O  oxygen 15-labelled water
LV  left ventricular
MBF  myocardial blood flow
MMRO2  myocardial oxygen consumption
PET  positron emission tomography
RPP  rate pressure product
SBP  systolic blood pressure
SF  shortening fraction
SFnorm  regions not demonstrating post-
ischemic dysfunction
SFdysfunction  regions demonstrating post-ischemic
dysfunction
SPECT  single photon emission computed
tomography
15O2  oxygen 15-labelled oxygen
Table 1. Patient Details





1 50 Atenolol, amlodipine, ISMN 40 LAD 64% Diag 52%, Cx 54%, RCA 100%
2 56 Diltiazem, ISMN 15 LAD 59%, RCA 71%
3 70 Atenolol 20 LAD 100%, Cx 57%, RCA 85%
4 71 Amlodipine, ISMN 15 Diag 54%, Cx 74%, RCA 83%
5 60 Atenolol 15 LAD 58%, Cx 100%, RCA 91%
6 61 Bisoprolol, nicorandil 10 LAD 100%, RCA 54%
7 71 Nifedipine, lisinopril 30 Diag 57%, Cx 68%, RCA 96%
8 56 Atenolol, amlodipine, lisinopril 20 LAD 78%
9 52 Atenolol 20 LAD 100%, Diag 85%, Cx 69%, RCA 85%
10 63 Atenolol, bendrofluazide 20 LAD 100%, Cx 69%, RCA 89%
11 62 Diltiazem 30 Diag 60%, RCA 100%
12 60 Atenolol 30 LAD 100%, Cx 47%, RCA 80%
13 66 Amlodipine, ISMN 30 LAD 60%, Diag 91%, Cx 84%, RCA 91%
14 59 Atenolol, ISMN, losartan 20 LAD 100%, Diag 54%, Cx 94%, RCA 61%
61.2  6.6 21.8  8.0
Cx  circumflex coronary artery; Diag  diagonal branch; LAD  left anterior descending coronary artery; QCA  quantitative coronary angiography; RCA  right coronary
artery.
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traced at end diastole, timed as the closure of the mitral
valve leaflets and, at end systole, defined as the point of
maximal inward excursion of the endocardial contour. The
centerline method was used to assess regional LV function
calculated as the difference between the end-diastolic and
end-systolic endocardial tracings. The deviation from the
centerline of 100 chords around the LV circumference is
calculated after correction for the end-diastolic circumfer-
ence and expressed as a percentage-shortening fraction (SF).
Each apical view of the LV is divided into six segments,
and the SF of the chords in each segment is averaged so that
a total of 12 values are obtained (six AP4CH and six
AP2CH). Post-ischemic dysfunction (SFdysfunction) was
defined as a reduction in SF of 30% at 30 min after
peak dobutamine and other regions that did not demon-
strate post-ischemic dysfunction defined as nondysfunc-
tional (SFnorm). Left ventricular volumes at end diastole and
end systole were calculated using the biplane disk method
and global ejection fraction (EF) derived as previously
described (11). The coefficient of repeatability for this
method is 2.6% as assessed by the method of Bland and
Altman (12).
PET scanning procedure. Positron emission tomography
scans were performed using an ECAT 931-08/12 15-slice
tomograph (CTI/Siemens, Knoxville, Tennessee). After a
20-min transmission scan, the blood pool was imaged by
inhalation of tracer amounts of 15O-labelled carbon mon-
oxide ([C15O] 3 MBqml1 at 500 mlmin1 for 4 min).
Myocardial blood flow was then measured using H2
15O
(10 MBq/kg) as previously described (13). The measure-
ment of regional MMRO2 was performed using a build-up
method as previously described (14); following a back-
ground frame of 30 s, 15O2 was inhaled for 5 min, and 10
additional 30-s frames were acquired. The scans were
repeated after dobutamine stress (Fig. 1).
PET image processing. The acquired sinograms were
corrected for attenuation and reconstructed as previously
described (13). The blood pool was identified from the
C15O scan and myocardial images generated directly from
the dynamic H2
15O data (15). Regions of interest were
placed over the lungs for the variate and covariate factors
(myocardial and blood time-activity curves) for modeling
the factor sinograms by means of the recently reported linear
dimension reduction (15). Factor images were generated by
iterative reconstruction (15) and resliced along the short
axis. The LV was divided into 12 regions of interest
(anterior, septal, lateral and inferior [basal, mid and apical])
comparable to those used for echocardiographic analysis and
projected onto the dynamic H2
15O and 15O2 images to
obtain arterial and myocardial time-activity curves. A single
tissue compartment tracer kinetic model was used to calcu-
late regional MBF (ml/min per g) as previously described
(15), which offers excellent reproducibility (13). The time-
activity curves for the myocardial regions were integrated to
facilitate calculation of MMRO2 (14).
To correct for the changes in MBF secondary to the
increase in cardiac workload, MBF and MMRO2 was also
corrected for the rate pressure product (RPP) (13).
Statistical analysis. Data are presented as mean  95%
confidence intervals. The primary end points were based on
the effects of pharmacologic stress on the echocardiographic
parameters of LV function (EF, SFdysfunction and SFnorm)
and MBF at baseline, peak stress and during recovery. All
echocardiographic data met the assumption of homogeneity
of variances required for analysis of variance (ANOVA).
Echocardiographic parameters, MBF and hemodynamic
parameters were compared using one-way ANOVA with a
design for repeated measures, with Bonferroni’s test to
correct for multiple comparisons.
The values of MBF and MMRO2 in SFdysfunction and
SFnorm regions were compared using an unpaired t test. The
values of regional LV function for each stenosis severity
subset were compared by one-way ANOVA with a design
for repeated measures as described above. The change of
regional function 30 min after peak stress compared with
baseline for each subset of stenosis severity was assessed
using an unpaired t test. A value of p 0.05 was considered
significant for all analyses.
Figure 1. Study protocol demonstrating the relative timings for the positron emission tomography and echocardiographic acquisitions. C15O 
15O-labelled carbon monoxide; H2
15O  15O-labelled water; TR  transmission scan; 15O2 
15O-labelled oxygen.
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RESULTS
Four patients did not proceed to the PET studies as their
echocardiographic windows precluded images of sufficient
quality for detailed regional quantitative analysis. In the 14
patients with a satisfactory baseline echocardiogram, the
mean baseline EF was 64.5 (61.5% to 67.2%). The dobut-
amine infusion was stopped at the patient’s request due to
chest pain in 12 patients, a rise in systolic blood pressure
(SBP) to 220 mm Hg in Patient 5 and a fall in SBP in
Patient 12. The mean dose of dobutamine administered was
21.8 g/kg per min (17.2 to 26.4 g/kg per min) (Table 1),
and maximal ST-segment depression at peak dobutamine
was 0.87 mm (0.52 mm to 1.22 mm). The RPP was higher
at the time of the last H2
15O scan compared with baseline
(10,483 [8,696 to 12,270] vs. 8,554 [7,683 to 9,427] mm
Hg  beats/min, p  0.05) due to a persisting elevation of
heart rate (71.2 [63.5 to 78.9] vs. 59.9 [55.62 to 64.2]
beats/min, p  0.01), although SBP was no different at
baseline compared with recovery (142.7 [133.0 to 152.4]
and 145.6 [134.1 to 157.2], respectively, p  NS).
Global EF. At 30 and 45 min after dobutamine stress, EF
was 59.1% (55.8% to 62.4%) and 61.2% (58.2% to 64.2%)
(p  0.001 and p  0.05 vs. baseline, respectively) (Fig. 2,
A). At 1 h and 2 h after peak stress, EF was 62.8% (60.4%
to 65.3%) and 64.7% (61.4% to 68.0%) (both: p  NS vs.
baseline). In nine of the 14 patients, global EF was reduced
by 5% at 30 min.
Regional function. All patients, except Patient 3, demon-
strated a reduction in SF of30% in at least one LV region.
Thirty minutes after peak dobutamine, the SFdysfunction was
reduced compared with the baseline value (1.96 [1.67 to
2.26] vs. 3.73 [3.39 to 4.07], p 0.001) and remained lower
45 (2.86 [2.53 to 3.19], p  0.001 vs. baseline) and 60 min
(3.12 [2.82 to 3.41], p  0.05 vs. baseline) after peak stress
(Fig. 2, A). However, SFdysfunction had returned to baseline
2 h after stress (3.68 [3.34 to 4.02], p  NS vs. baseline).
The SFnorm was 3.77 (3.58 to 3.95) at baseline and
remained unchanged after stress at 30, 45, 60 and 120 min
after peak dobutamine (3.58 [3.41 to 3.76], 3.48 [3.29 to
3.67], 3.63 [3.44 to 3.82] and 3.72 [3.54 to 3.89], respec-
tively: all: p  NS vs. baseline).
MBF. Baseline MBF to regions that exhibited reduced
systolic function after dobutamine (SFdysfunction) was 0.88
(0.82 to 0.99) ml/min per g and 0.89 (0.81 to 0.90) ml/min
per g in SFnorm regions (p  NS). Myocardial blood flow
corrected for the RPP was 1.07 (1.01 to 1.23) ml/min per g
and 1.05 (1.00 to 1.12) ml/min per g, respectively (pNS).
At peak stress, MBF increased both in SFdysfunction and
SFnorm regions (1.44 [1.25 to 1.64] ml/min per g and 1.71
[1.62 to 1.81] ml/min per g, respectively, both: p  0.001
vs. baseline) (Fig. 3A), but the increase in SFdysfunction
regions was significantly lower than it was in SFnorm regions
(p  0.01). After dobutamine, MBF to SFdysfunction regions
was 1.09 (0.75 to 1.37) ml/min/g (p  NS compared with
baseline), and in SFnorm regions it was 1.11 (1.04 to 1.27)
ml/min per g (p  0.001 compared with baseline). This
difference, however, was absent when MBF was corrected
for RPP (Fig. 3B).
MMRO2. At baseline, MMRO2 did not differ between
SFdysfunction and SFnorm (16.64 [10.16 to 16.18] ml/min per
100 g vs. 12.48 [11.68 to 13.28] ml/min per 100 g,
respectively, p  NS). After dobutamine stress, when
function was impaired but subsequently recovered and MBF
had returned to baseline, MMRO2 in SFdysfunction was
Figure 2. (A) Ejection fraction (%) versus time after peak dobutamine (mean  95% confidence interval [CI]). (B) Shortening fraction of dysfunctional
and non-dysfunctional remote regions (mean  95% CI). SFdysfunction  post-ischemic dysfunction; SFnorm  remote regions not demonstrating
post-ischemic dysfunction. *p  0.001; †p  0.05.
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Figure 3. (A and B) Myocardial blood flow (MBF) to dysfunctional and remote regions at baseline, peak dobutamine and in recovery. Flow is given as raw
data (A) and corrected for the rate pressure product (RPP) (MBFcorr  (MBFbaseline/RPP)  10
4). (B) All recovery flow  NS compared with baseline
except remote uncorrected flow: (*p  0.001 compared with baseline uncorrected flow). (C) Myocardial oxygen consumption to dysfunctional and remote
regions at baseline and in recovery: (*p  0.001 compared with corresponding baseline value). SFdysfunction  post-ischemic dysfunction; SFnorm  regions
not demonstrating post-ischemic dysfunction.
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reduced but was not significantly different from baseline
(11.68 [8.43 to 15.30] ml/min per 100 g), whereas in SFnorm
there was an increase in MMRO2 after dobutamine (14.66
[13.13 to 16.19] ml/min per 100 g, p  0.01 vs. baseline),
although this was no different from SFdysfunction in recovery
(Fig. 3C).
Relation between stenosis severity and degree of myocar-
dial dysfunction. The degree of myocardial dysfunction
was assessed for regions subtended by coronary arteries of
differing stenosis severities (16). Stenosis severity was cate-
gorized as 50%, 50% to 80% and 80% of the luminal
diameter. When all 14 patients were assessed, regional
function 30 min after peak stress did not change compared
with baseline in regions subtended by a stenosis of 50%
(96.3% [87.6 to 105.1] of baseline SF, p  NS). In regions
subtended by arteries with a stenosis of 50% to 80% and in
those with 80% stenosis, SF was 89.4% (84.0% to 94.8%)
and 88.3% (77.3% to 99.4%) of baseline SF, respectively
(both: p  0.01 vs. baseline).
The relation between the stenosis severity and severity of
regional LV dysfunction 30 min after dobutamine was also
assessed in the nine patients with 5% reduction in global
EF. In these patients, the severity of regional LV dysfunc-
tion was related to the degree of stenosis and inversely to the
increase in MBF at peak dobutamine (Fig. 4). For regions
subtended by an artery with a 50% stenosis (n  24), SF
was 93.9 (83.4 to 104.4) of baseline function 30 min after
peak stress (p  NS) with a peak MBF of 2.01 (1.71 to
2.31) ml/min per g.
In regions subtended by an artery with a 50% to 80%
stenosis (n  62), SF 30 min after peak dobutamine was
85.4% (80.0% to 90.9%) of baseline function (p  0.001)
with a peak flow of 1.75 (1.65 to 1.85) ml/min per 100 g
(p  0.03 compared with 50% stenosis). In regions
subtended by an artery with a 80% stenosis (n  22), SF
30 min after peak dobutamine was 67.4% (56.2% to 78.7%)
of baseline function (p  0.001) with a peak flow of 1.47
(1.33 to 1.60) ml/min/g (p  0.003 compared with 50% to
80% stenosis and p 0.002 compared with50% stenosis).
DISCUSSION
This study demonstrates that absolute MBF and MMRO2
measured after an episode of dobutamine-induced ischemia
in myocardium exhibiting reversible contractile dysfunction
are not different from baseline. Although the simultaneous
measurement of regional LV function by echocardiography
and the acquisition of data obtained using PET is not
possible, we have demonstrated a significant, but reversible,
impairment in regional LV function immediately after
confirming that MBF is not reduced. In addition, we have
shown that the degree of such dysfunction is related to the
severity of the preceding episode of demand ischemia that,
in turn, is related to the stenosis severity of the coronary
artery subtending that region. The results of this study
confirm that myocardial stunning can occur after an episode
of demand ischemia in patients with CAD and stable
angina pectoris and that the metabolic rate of oxygen
consumption by stunned myocardium is not reduced.
MBF and myocardial dysfunction. Myocardial stunning
is defined as the post-ischemic LV dysfunction that persists
in the absence of irreversible damage despite normal or
near-normal myocardial perfusion (1,2). Prerequisites for
confirming stunning involve both the demonstration of fully
reversible LV dysfunction and normal or near-normal MBF
when LV function is impaired. A number of studies have
reported reversible LV dysfunction after exercise-induced
ischemia in patients with CAD (8,11,17). Only one study
Figure 4. (A) Shortening fraction (SF) as a percentage change from baseline (mean 95% confidence interval [CI]). *p 0.001. (B) Peak myocardial blood
flow (MBF) (mean  95% CI) versus stenosis severity (% of luminal diameter) in nine patients.
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using SPECT has demonstrated an absence of perfusion
defects in regions with reversible LV dysfunction (8). Single
photon emission computed tomography offers qualitative, or
at best semiquantitative, data regarding relative changes in
perfusion and, therefore, that study could only demonstrate
a lack of major differences in MBF between dysfunctional
and remote regions. More recently, Gerber et al. (18) have
demonstrated normal absolute MBF using PET and the
flow tracer nitrogen 13-labelled ammonia in patients with
reversible LV dysfunction after an episode of unstable
angina who were successfully treated by angioplasty. In
contrast with that study (18) we were able to assess resting
LV function and have demonstrated reversible LV dysfunc-
tion that is similar in duration to other published work
(8,11,17). We have also shown that myocardial ischemia in
patients with stable angina is not usually due to an absolute
reduction in MBF but to a blunted rise in peak MBF
compared with regions that do not develop dysfunction. In
this setting ischemia fulfills the classic definition of an
imbalance between demand and supply.
MMRO2 and stunning. Little data exist regarding
MMRO2 to human stunned myocardium. The results of
many animal studies support the theory of an “oxygen
paradox” (19) whereby, despite a marked reduction in
myocardial function, there is maintained oxygen consump-
tion. In an isolated heart preparation using global ischemia
to induce stunning MMRO2 has been found to be un-
changed from baseline (20,21). In a conscious, chronically
instrumented canine model of post-ischemic dysfunction,
Laxson et al. (22) found no change in MMRO2 to stunned
myocardium from baseline. Similar results have been dem-
onstrated in an anesthetized, open-chested canine (19).
Using PET and the tracer 1-11C-acetate as an indirect
assessment of regional and global MMRO2, oxygen con-
sumption to stunned myocardium has also been shown to be
preserved in anesthetized dogs (23). In contrast with these
findings, others have found a decrease in MMRO2 in
proportion to the corresponding reduction in ventricular
function (24).
Regarding the regional assessment of MMRO2 to acutely
stunned myocardium in man, little data exist. In the recent
study by Gerber et al. (18), regional MMRO2 to dysfunc-
tional, but viable, segments was not different from remote
regions. Due to the aforementioned time course of recovery
in LV function in this study, there was no baseline data
comparing a basal MMRO2. There is, therefore, no study to
date in the human assessing regional MMRO2 to acutely
stunned myocardium, assessing values both before ischemia
and in the post-ischemic period during the post-ischemic
LV dysfunction. Our data would support the hypothesis
that the stunned myocardium shows a marked reduction in
function, and during this dysfunction there was a trend for
a reduction in MMRO2, although this difference did not
achieve statistical significance. Overall, the oxygen utiliza-
tion is inappropriately high for the degree of dysfunction
seen. It would appear that this is due to inappropriate
energy requirements for excitation-contraction coupling
(20), and it has been suggested that, as well as the functional
stunning that is seen, a “metabolic stunning” occurs (21).
Myocardial dysfunction and the severity of ischemia. We
have demonstrated a relation between the degree of regional
myocardial dysfunction and the impairment of peak MBF
during stress. In animal models, where ischemia is usually
induced by coronary ligation to reduce regional myocardial
perfusion, it is generally accepted that the severity of
myocardial stunning is related to the intensity and duration
of the preceding bout of ischemia (25,26), although the
former is more important (7). In patients with CAD,
demand ischemia follows an inadequate increase in blood
flow to meet an increase in myocardial work. In this study
dobutamine was used to increase myocardial work as the
movement of exercise precludes satisfactory PET imaging to
be acquired. We have previously demonstrated that the
resultant degree of LV dysfunction is similar after either
form of demand-ischemia, although it is not possible to
quantify the degree or duration of ischemia in an individual
patient (17). Furthermore, dobutamine stress results in a
progressive blunting of myocardial hyperemia with increas-
ing coronary artery stenosis severity (27). This has been
further confirmed in the present study, where myocardial
regions subtended by a coronary artery with a higher-grade
stenosis have a greater attenuation in peak MBF. In
addition, such regions have now been shown to exhibit more
marked reversible systolic dysfunction.
Although we have demonstrated a reduction in peak
MBF with increasing stenosis severity, it is not possible to
define the degree to which MBF must be reduced before
ischemia ensues. Without continuous flow measurements, it
is not possible to assess the true duration of ischemia since
noninvasive markers of ischemia are unreliable. The occur-
rence and duration of chest pain is subjective and unlikely to
be a valid marker. ST-segment depression with dobutamine
has been demonstrated to have a sensitivity of only about
50% (28) and would, therefore, not enable an accurate
estimation of the duration of ischemia (28).
Study limitations. In this study the assessment of MBF
and MMRO2 after dobutamine was made immediately
before the echocardiographic data acquisition 30 min after
the end of the dobutamine infusion and not simultaneously.
It is impossible to collect echocardiographic and PET data
concurrently due to movement artefact and patient position-
ing. We believe that by demonstrating normal MBF before
showing that LV function was still reduced confirms the
presence of stunning. Our data are in accordance with
reports from other workers using SPECT to assess myocar-
dial perfusion who demonstrated no perfusion abnormalities
30 min after an ischemic episode (8).
We noted that for all 14 patients there was no significant
difference in the degree of stunning between regions sub-
tended by coronary arteries with a stenosis of 50% to 80% or
80%. However, in those patients in whom the overall EF
was reduced 5%, there was a significant relation between
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the degree of stunning and the severity of the preceding
episode of ischemia. This is most likely because many of the
stenoses 80% were total occlusions and regions with
normal resting function subtended by these arteries probably
had a good collateral supply, thus reducing or preventing
ischemia and, hence, stunning, although we did not assess
the degree of collateralization. Finally, it is recognized that
not all patients with stable CAD develop myocardial stun-
ning (11).
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